1. Clinical & Scientific Overview
Abiraterone Acetate (TIP-MED-000569, Reference Code [ONC-20]) is classified under
Oncology & Antineoplastic Medicines as a Hormonal Oncology Therapy (Androgen Biosynthesis Inhibitor) • Selective Irreversible CYP17A1 (17-Alpha-Hydroxylase/C17,20-Lyase) Inhibitor.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
Zytiga (Janssen / Johnson & Johnson), Xbira (Cipla Ltd), Abirapro (Glenmark Pharmaceuticals)
Uncoated/Film-Coated Tablet: 250 mg, 500 mg
Oncology Specialisation & Cytotoxic Safety Protocol
Hormonal Oncology Therapy (Androgen Biosynthesis Inhibitor)
Antineoplastic Hormonal Agent
Standard Regimen & Cycle Context: 1,000 mg orally once daily on an EMPTY STOMACH (at least 1 hour before or 2 hours after food) PLUS Prednisolone 5 mg once or twice daily.
Signature Dose-Limiting Toxicities & Organ Monitoring: MINERALOCORTICOID EXCESS SYNDROME: Blocking 17-alpha-hydroxylase causes feedback ACTH surge, driving deoxycorticosterone and corticosterone synthesis -> hypertension, hypokalaemia, and fluid retention/oedema (prevented by mandatory co-administration of low-dose prednisolone to suppress ACTH); CRITICAL FOOD EFFECT: Taking standard Abiraterone with a high-fat meal increases systemic exposure (AUC) by 10-FOLD and Cmax by 17-FOLD, causing severe hepatotoxicity!
Extravasation, Premedication & Safe Cytotoxic Handling: Counsel patient emphatically: Take Abiraterone 1,000 mg strictly on an empty stomach with water, never skip companion Prednisolone, and monitor BP, serum potassium, and AST/ALT/bilirubin every 2 weeks for the first 3 months.
3. Mechanism of Action & Pharmacodynamics
Prodrug converted to abiraterone, which irreversibly inhibits CYP17A1 in the testes, adrenal glands, and prostate tumour tissue, blocking conversion of pregnenolone and progesterone into DHEA and androstenedione.
4. Therapeutic Indications & Evidence-Supported Uses
- Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC) and Metastatic Castration-Resistant Prostate Cancer (mCRPC) ALWAYS in combination with Prednisolone
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): 1,000 mg orally once daily on an EMPTY STOMACH (at least 1 hour before or 2 hours after food) PLUS Prednisolone 5 mg once or twice daily.
Administration & Meal Timing: 1,000 mg orally once daily on an EMPTY STOMACH (at least 1 hour before or 2 hours after food) PLUS Prednisolone 5 mg once or twice daily.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Abiraterone Acetate or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: MINERALOCORTICOID EXCESS SYNDROME: Blocking 17-alpha-hydroxylase causes feedback ACTH surge, driving deoxycorticosterone and corticosterone synthesis -> hypertension, hypokalaemia, and fluid retention/oedema (prevented by mandatory co-administration of low-dose prednisolone to suppress ACTH); CRITICAL FOOD EFFECT: Taking standard Abiraterone with a high-fat meal increases systemic exposure (AUC) by 10-FOLD and Cmax by 17-FOLD, causing severe hepatotoxicity!
8. Adverse Effects Profile
- MINERALOCORTICOID EXCESS SYNDROME: Blocking 17-alpha-hydroxylase causes feedback ACTH surge, driving deoxycorticosterone and corticosterone synthesis -> hypertension, hypokalaemia, and fluid retention/oedema (prevented by mandatory co-administration of low-dose prednisolone to suppress ACTH); CRITICAL FOOD EFFECT: Taking standard Abiraterone with a high-fat meal increases systemic exposure (AUC) by 10-FOLD and Cmax by 17-FOLD, causing severe hepatotoxicity!
- MINERALOCORTICOID EXCESS SYNDROME: Blocking 17-alpha-hydroxylase causes feedback ACTH surge, driving deoxycorticosterone and corticosterone synthesis -> hypertension, hypokalaemia, and fluid retention/oedema (prevented by mandatory co-administration of low-dose prednisolone to suppress ACTH); CRITICAL FOOD EFFECT: Taking standard Abiraterone with a high-fat meal increases systemic exposure (AUC) by 10-FOLD and Cmax by 17-FOLD, causing severe hepatotoxicity!
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- MINERALOCORTICOID EXCESS SYNDROME: Blocking 17-alpha-hydroxylase causes feedback ACTH surge, driving deoxycorticosterone and corticosterone synthesis -> hypertension, hypokalaemia, and fluid retention/oedema (prevented by mandatory co-administration of low-dose prednisolone to suppress ACTH); CRITICAL FOOD EFFECT: Taking standard Abiraterone with a high-fat meal increases systemic exposure (AUC) by 10-FOLD and Cmax by 17-FOLD, causing severe hepatotoxicity!
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Counsel patient emphatically: Take Abiraterone 1,000 mg strictly on an empty stomach with water, never skip companion Prednisolone, and monitor BP, serum potassium, and AST/ALT/bilirubin every 2 weeks for the first 3 months.
Pharmacist Patient Counselling Points:
- Counsel patient emphatically: Take Abiraterone 1,000 mg strictly on an empty stomach with water, never skip companion Prednisolone, and monitor BP, serum potassium, and AST/ALT/bilirubin every 2 weeks for the first 3 months.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: Counsel patient emphatically: Take Abiraterone 1,000 mg strictly on an empty stomach with water, never skip companion Prednisolone, and monitor BP, serum potassium, and AST/ALT/bilirubin every 2 weeks for the first 3 months.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-19] Enzalutamide — Hormonal Oncology Therapy (Antiandrogen) • Second-Generation Non-
- [ONC-21] Osimertinib Mesylate — Targeted Therapy (EGFR TKI) • Third-Generation Mutant-Selective I
- [ONC-22] Lenvatinib Mesylate — Targeted Therapy (Multi-Kinase Anti-Angiogenic TKI) • Multi-Targe
- [ONC-23] Ibrutinib — Targeted Therapy (BTK Inhibitor) • First-in-Class Irreversible Br
